6亿融资耗尽、并购砸超11亿，多宁生物“烧钱”扩张难换盈利

Core Viewpoint - Doning Bio, a domestic provider of serum-free culture media, is attempting its third IPO submission to the Hong Kong Stock Exchange, aiming for profitability by the third quarter of 2025, despite facing significant challenges including related party transactions, goodwill impairment risks, and short-term debt pressures [1][2][26]. Company Overview - Founded in 2005, Doning Bio started as a small technology company focused on cell culture media, which is essential for the growth of animal cells used in research and biopharmaceutical production [3]. - The company has evolved into a one-stop solution provider for biopharmaceutical processes, offering products and services that cover the entire development and commercialization process [4][5]. Business Performance - Doning Bio's revenue increased from 597 million RMB in 2021 to 840 million RMB in 2024, but the growth rate significantly slowed from 208% to 3.54% [7]. - The company reported a net profit of 234 million RMB in 2021, which plummeted to 38 million RMB in 2022, and further turned into a net loss of 310 million RMB in 2023, with a slight recovery to a loss of 24 million RMB in 2024 [7][8]. Financial Challenges - The company faces a significant financial burden with short-term borrowings of 389 million RMB against cash reserves of only 302 million RMB, indicating a tight liquidity situation [21]. - Doning Bio's goodwill stands at 843 million RMB, raising concerns about potential impairment if the performance of acquired entities does not meet expectations [1][19]. Investment and Acquisition Strategy - Since 2016, under the leadership of CEO Wang Meng, Doning Bio has pursued an aggressive acquisition strategy, spending over 1.142 billion RMB in cash for acquisitions to build a comprehensive biopharmaceutical service chain [18][19]. - The company has raised a total of 600 million RMB in financing prior to its IPO, but these funds have been fully utilized, primarily for R&D and acquisitions [14][15]. Related Party Transactions - WuXi Biologics, as the second-largest shareholder and primary customer, has raised concerns regarding the fairness of related party transactions, which accounted for significant portions of Doning Bio's revenue [26]. - In the years 2023 to 2025, WuXi Biologics contributed 1.2 billion RMB, 930 million RMB, and 800 million RMB to Doning Bio's revenue, representing 14.9%, 10.9%, and 12.1% of total revenue respectively [26]. IPO Prospects - The upcoming IPO is seen as a critical opportunity for Doning Bio to raise funds to alleviate financial pressures and support strategic expansion, but the company must demonstrate sustainable profitability and operational independence to succeed [23][24][26].